S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
NASDAQ:OCUP

Ocuphire Pharma Stock Forecast, Price & News

$3.66
-0.25 (-6.39%)
(As of 12/1/2021 01:21 PM ET)
Add
Compare
Today's Range
$3.65
$4.00
50-Day Range
$3.40
$5.38
52-Week Range
$3.35
$13.81
Volume
9,762 shs
Average Volume
1.06 million shs
Market Capitalization
$63.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.15
30 days | 90 days | 365 days | Advanced Chart
Receive OCUP News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter.


Ocuphire Pharma logo

About Ocuphire Pharma

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Headlines

Ocuphire Pharma Sees Unusually High Options Volume (NASDAQ:OCUP)
November 24, 2021 |  americanbankingnews.com
HC Wainwright Begins Coverage on Ocuphire Pharma (NASDAQ:OCUP)
November 24, 2021 |  americanbankingnews.com
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Short Interest Update
November 19, 2021 |  americanbankingnews.com
Ocuphire Pharma, Inc.(OCUP)
November 13, 2021 |  fool.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCUP
Employees
5
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($1.24) per share

Profitability

Net Income
$-24.62 million
Pretax Margin
-66,078.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
13,856,000
Market Cap
$63.32 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/09/2022

MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

372nd out of 1,392 stocks

Pharmaceutical Preparations Industry

167th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Ocuphire Pharma (NASDAQ:OCUP) Frequently Asked Questions

Is Ocuphire Pharma a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocuphire Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ocuphire Pharma stock.
View analyst ratings for Ocuphire Pharma
or view top-rated stocks.

Are investors shorting Ocuphire Pharma?

Ocuphire Pharma saw a drop in short interest in October. As of October 29th, there was short interest totaling 445,400 shares, a drop of 27.0% from the October 14th total of 610,200 shares. Based on an average daily volume of 208,200 shares, the short-interest ratio is presently 2.1 days.
View Ocuphire Pharma's Short Interest
.

When is Ocuphire Pharma's next earnings date?

Ocuphire Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Ocuphire Pharma
.

How were Ocuphire Pharma's earnings last quarter?

Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.11.
View Ocuphire Pharma's earnings history
.

What price target have analysts set for OCUP?

5 equities research analysts have issued 1 year price objectives for Ocuphire Pharma's shares. Their forecasts range from $20.00 to $26.00. On average, they anticipate Ocuphire Pharma's share price to reach $22.60 in the next year. This suggests a possible upside of 517.5% from the stock's current price.
View analysts' price targets for Ocuphire Pharma
or view top-rated stocks among Wall Street analysts.

Who are Ocuphire Pharma's key executives?

Ocuphire Pharma's management team includes the following people:
  • Mina Patel Sooch, President, Chief Executive Officer & Director
  • Bernhard Hoffmann, Vice President-Corporate Development & Operations
  • Amy Rabourn, Chief Accounting Officer & Vice President-Finance
  • Mitchell Brigell, Head-Clinical Development & Strategy
  • Drey Coleman, Director-Clinical Operations & Vendor Management

What is Ocuphire Pharma's stock symbol?

Ocuphire Pharma trades on the NASDAQ under the ticker symbol "OCUP."

Who are Ocuphire Pharma's major shareholders?

Ocuphire Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.47%), Two Sigma Advisers LP (0.26%), Two Sigma Investments LP (0.22%), Citadel Advisors LLC (0.00%), Millennium Management LLC (0.16%) and LPL Financial LLC (0.12%). Company insiders that own Ocuphire Pharma stock include James S J Manuso and Jay Pepose.
View institutional ownership trends for Ocuphire Pharma
.

Which major investors are buying Ocuphire Pharma stock?

OCUP stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Citadel Advisors LLC, Millennium Management LLC, LPL Financial LLC, and Morgan Stanley. Company insiders that have bought Ocuphire Pharma stock in the last two years include James S J Manuso, and Jay Pepose.
View insider buying and selling activity for Ocuphire Pharma
or or view top insider-buying stocks.

How do I buy shares of Ocuphire Pharma?

Shares of OCUP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocuphire Pharma's stock price today?

One share of OCUP stock can currently be purchased for approximately $3.66.

How much money does Ocuphire Pharma make?

Ocuphire Pharma has a market capitalization of $63.32 million.

How many employees does Ocuphire Pharma have?

Ocuphire Pharma employs 5 workers across the globe.

What is Ocuphire Pharma's official website?

The official website for Ocuphire Pharma is www.ocuphire.com.

Where are Ocuphire Pharma's headquarters?

Ocuphire Pharma is headquartered at 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850.

How can I contact Ocuphire Pharma?

Ocuphire Pharma's mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at (248) 681-9815, via email at [email protected], or via fax at 240-268-5310.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.